摘要
司美格鲁肽作为新型长效胰高血糖素样肽1(GLP-1)受体激动剂,在肥胖及相关代谢性疾病中的治疗作用显著。本文从作用机制、临床应用及现存挑战3个维度,系统综述司美格鲁肽治疗肥胖及相关代谢性疾病的研究进展,发现其作用机制涉及多器官协同调控和代谢干预,临床应用包括治疗肥胖、糖尿病、多囊卵巢综合征、肝脏相关代谢综合征,并在心血管和肾脏保护方面展现出突破性价值;但其在不良反应、个体化治疗、经济可及性、伦理争议和风险方面仍面临多重挑战。未来需进一步积累司美格鲁肽的长期安全性数据、优化联合治疗方案、解决特殊人群个体化用药等关键问题,以充分发挥其临床应用价值。
As a novel long-acting glucagon-like peptide-1(GLP-1)receptor agonist,semaglutide plays a pivotal role in the treatment of obesity and related metabolic diseases.This article systematically reviews the research progress of semaglutide in the treatment of obesity and related metabolic diseases from three aspects:mechanism of action,clinical applications,and existing challenges.It is found that its mechanism of action involves multi-organ synergistic regulation and metabolic intervention.Its clinical applications encompass the treatment of obesity,diabetes,polycystic ovary syndrome,and liver-related metabolic syndromes,and it demonstrates groundbreaking value in cardiovascular and renal protection.However,it still faces multiple challenges in terms of adverse reactions,individualized treatment,economic accessibility,ethical controversies,and risks.In the future,it is essential to further accumulate long-term safety data on semaglutide,optimize combination treatment regimens,and address key issues such as individualized medication for special populations,in order to fully realize its clinical application value.
作者
章鑫莹
周盈盈
傅晓丹
张险峰
ZHANG Xinying;ZHOU Yingying;FU Xiaodan;ZHANG Xianfeng(Fourth Clinical College,Zhejiang Chinese Medical University,Hangzhou 310051,China;Dept.of Endocrinology and Metabolism,Hangzhou First People’s Hospital,Hangzhou 310006,China)
出处
《中国药房》
北大核心
2025年第17期2205-2210,共6页
China Pharmacy
基金
浙江省软科学研究计划项目(No.2024C35060)
浙江省医药卫生科技计划项目(No.2025KY1092)。
关键词
司美格鲁肽
GLP-1受体激动剂
肥胖
代谢性疾病
临床挑战
semaglutide
glucagon-like peptide-1 receptor agonist
obesity
metabolic diseases
clinical challenges
作者简介
第一作者:章鑫莹,硕士研究生。研究方向:内分泌与代谢。E-mail:17858186095@163.com;通信作者:张险峰,教授,硕士生导师。研究方向:内分泌与代谢。E-mail:zxf2541@zju.edu.cn。
